Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could tame debilitating eye inflammation, major trial underway

NCT ID NCT06431373

Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral medication called brepocitinib in adults with active uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can prevent the disease from worsening and help maintain vision. About 371 participants will receive either the drug or a placebo, and researchers will monitor them for up to 48 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

371 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects (18-75 years old) * Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis) * Active uveitic disease in at least 1 eye * Weight \> 40 kg with a body mass index ≤ 40 kg/m2 Exclusion Criteria: Has confirmed or suspected current diagnosis of infectious uveitis History of or have: 1. Lymphoproliferative disorder 2. active malignancy 3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.) 4. thrombosis or cerebrovascular ischemic event disease within the last 12 months 5. a high risk for herpes zoster reactivation 6. active or recent infections

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Panuveitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intermediate uveitis panuveitis posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uveitis Uveitis, intermediate Uveitis, posterior

Contacts and locations

Locations

  • Clinical Trial Site

    Phoenix, Arizona, 85020, United States

  • Clinical Trial Site

    Phoenix, Arizona, 85054, United States

  • Clinical Trial Site

    Bakersfield, California, 93309, United States

  • Clinical Trial Site

    Beverly Hills, California, 90211, United States

  • Clinical Trial Site

    Fullerton, California, 92835, United States

  • Clinical Trial Site

    Irvine, California, 92697, United States

  • Clinical Trial Site

    La Jolla, California, 92093, United States

  • Clinical Trial Site

    Los Angeles, California, 90033, United States

  • Clinical Trial Site

    Los Angeles, California, 90095, United States

  • Clinical Trial Site

    Modesto, California, 95356, United States

  • Clinical Trial Site

    Sacramento, California, 92825, United States

  • Clinical Trial Site

    Aurora, Colorado, 80045, United States

  • Clinical Trial Site

    Denver, Colorado, 80246, United States

  • Clinical Trial Site

    Fort Lauderdale, Florida, 33308, United States

  • Clinical Trial Site

    St. Petersburg, Florida, 33711, United States

  • Clinical Trial Site

    Chicago, Illinois, 60637, United States

  • Clinical Trial Site

    Oak Park, Illinois, 60304, United States

  • Clinical Trial Site

    Carmel, Indiana, 46290, United States

  • Clinical Trial Site

    Prairie Village, Kansas, 66208, United States

  • Clinical Trial Site

    Baltimore, Maryland, 21287, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02114, United States

  • Clinical Trial Site

    Waltham, Massachusetts, 02451, United States

  • Clinical Trial Site

    Ann Arbor, Michigan, 48105, United States

  • Clinical Trial Site

    Detroit, Michigan, 48201, United States

  • Clinical Trial Site

    Detroit, Michigan, 48202, United States

  • Clinical Trial Site

    Minneapolis, Minnesota, 55455, United States

  • Clinical Trial Site

    Rochester, Minnesota, 55905, United States

  • Clinical Trial Site

    St Louis, Missouri, 63108, United States

  • Clinical Trial Site

    Omaha, Nebraska, 68105, United States

  • Clinical Trial Site

    Palisades Park, New Jersey, 07650, United States

  • Clinical Trial Site

    Rochester, New York, 14642, United States

  • Clinical Trial Site

    Durham, North Carolina, 27705, United States

  • Clinical Trial Site

    Winston-Salem, North Carolina, 27157, United States

  • Clinical Trial Site

    Cleveland, Ohio, 44106, United States

  • Clinical Trial Site

    Cleveland, Ohio, 44195, United States

  • Clinical Trial Site

    Columbus, Ohio, 43212, United States

  • Clinical Trial Site

    Portland, Oregon, 97221, United States

  • Clinical Trial Site

    Portland, Oregon, 97239, United States

  • Clinical Trial Site

    Erie, Pennsylvania, 16507, United States

  • Clinical Trial Site

    Philadelphia, Pennsylvania, 19107, United States

  • Clinical Trial Site

    Philadelphia, Pennsylvania, 19141, United States

  • Clinical Trial Site

    Greenville, South Carolina, 29605, United States

  • Clinical Trial Site

    Nashville, Tennessee, 37232, United States

  • Clinical Trial Site

    Austin, Texas, 78712, United States

  • Clinical Trial Site

    Bellaire, Texas, 77401, United States

  • Clinical Trial Site

    Dallas, Texas, 75390, United States

  • Clinical Trial Site

    Houston, Texas, 77025, United States

  • Clinical Trial Site

    Katy, Texas, 77494, United States

  • Clinical Trial Site

    Plano, Texas, 75075, United States

  • Clinical Trial Site

    Round Rock, Texas, 78681, United States

  • Clinical Trial Site

    San Antonio, Texas, 78230, United States

  • Clinical Trial Site

    Madison, Wisconsin, 53705, United States

  • Clinical Trial Site

    Rosario, Santa Fe Province, 41076, Argentina

  • Clinical Trial Site

    Buenos Aires, 41076, Argentina

  • Clinical Trial Site

    Buenos Aires, C1015, Argentina

  • Clinical Trial Site

    Buenos Aires, C1061AAE, Argentina

  • Clinical Trial Site

    Buenos Aires, C1121, Argentina

  • Clinical Trial Site

    Sydney, New South Wales, 2000, Australia

  • Clinical Trial Site

    East Melbourne, Victoria, 3002, Australia

  • Clinical Trial Site

    Nedlands, Western Australia, 6009, Australia

  • Clinical Trial Site

    Linz, 04020, Austria

  • Clinical Trial Site

    Leuven, VI-Brabant, 3000, Belgium

  • Clinical Trial Site

    Prague, 128 08, Czechia

  • Clinical Trial Site

    Mannheim, Baden-Wurttemberg, 68167, Germany

  • Clinical Trial Site

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Clinical Trial Site

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Clinical Trial Site

    Münster, North Rhine-Westphalia, 48145, Germany

  • Clinical Trial Site

    Münster, North Rhine-Westphalia, 48149, Germany

  • Clinical Trial Site

    Kiel, 24105, Germany

  • Clinical Trial Site

    Mainz, 55131, Germany

  • Clinical Trial Site

    Thessaloniki, 54622, Greece

  • Clinical Trial Site

    Pécs, Baranya, 07623, Hungary

  • Clinical Trial Site

    Debrecen, Hajdú-Bihar, 04032, Hungary

  • Clinical Trial Site

    Budapest, Pest County, 01085, Hungary

  • Clinical Trial Site

    Budapest, 01133, Hungary

  • Clinical Trial Site

    Ashkelon, 7830604, Israel

  • Clinical Trial Site

    Haifa, 3109601, Israel

  • Clinical Trial Site

    Haifa, 3434104, Israel

  • Clinical Trial Site

    Holon, 58101, Israel

  • Clinical Trial Site

    Jerusalem, 9013102, Israel

  • Clinical Trial Site

    Jerusalem, 9112001, Israel

  • Clinical Trial Site

    Kfar Saba, 4428164, Israel

  • Clinical Trial Site

    Poria – Neve Oved, 1528801, Israel

  • Clinical Trial Site

    Tel Aviv, 6423906, Israel

  • Clinical Trial Site

    Tel Aviv, 69710, Israel

  • Clinical Trial Site

    Perugia, Umbria, 06129, Italy

  • Clinical Trial Site

    Milan, Italy

  • Clinical Trial Site

    Reggio Emilia, 42123, Italy

  • Clinical Trial Site

    Roma, 00184, Italy

  • Clinical Trial Site

    Barcelona, Catalonia, 08035, Spain

  • Clinical Trial Site

    Barcelona, 08028, Spain

  • Clinical Trial Site

    Madrid, 28-046, Spain

  • Clinical Trial Site

    Madrid, 28040, Spain

  • Clinical Trial Site

    Valladolid, 47011, Spain

  • Clinical Trial Site

    London, England, EC1V 2PD, United Kingdom

  • Clinical Trial Site

    London, England, SE1 7EH, United Kingdom

  • Clinical Trial Site

    Maidstone, Kent, ME169QQ, United Kingdom

  • Clinical Trial Site

    Middlesbrough, North Yorkshire, TS4 3BW, United Kingdom

  • Clinical Trial Site

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

  • Clinical Trial Site

    Sheffield, South Yorkshire, S10 2JF, United Kingdom

  • Clinical Trial Site

    Birmingham, West Midlands, B18 7QH, United Kingdom

  • Clinical Trial Site

    Bradford, Yorkshire, BD9 6TB, United Kingdom

  • Clinical Trial Site

    Birmingham, B1S 2GW, United Kingdom

  • Clinical Trial Site

    Bristol, BS1 2LX, United Kingdom

  • Clinical Trial Site

    Liverpool, L7 8XP, United Kingdom

  • Clinical Trial Site

    Manchester, M13 9WL, United Kingdom

  • NYU Langone Health

    New York, New York, 10017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.